# PDK4

## Overview
Pyruvate dehydrogenase kinase 4 (PDK4) is a gene that encodes the mitochondrial enzyme pyruvate dehydrogenase kinase 4, a member of the kinase family involved in the regulation of metabolic pathways. The PDK4 protein plays a pivotal role in energy metabolism by phosphorylating and inhibiting the pyruvate dehydrogenase complex (PDC), thereby modulating the conversion of pyruvate to acetyl-CoA and influencing the balance between glucose and fatty acid oxidation (Jeon2020Loss; Jeoung2010Role). This regulation is crucial for maintaining metabolic flexibility and energy homeostasis, particularly in tissues with high energy demands such as skeletal muscle, liver, and heart (Jeon2020Loss; Jeoung2010Role). PDK4 expression is tightly controlled by nutritional and hormonal signals, adapting to physiological conditions such as fasting and feeding (Jeon2020Loss; Connaughton2010Regulation). Alterations in PDK4 activity and expression are associated with various metabolic disorders and diseases, including diabetes, obesity, and certain cancers, highlighting its clinical significance (Pin2019PDK4; Jeon2020Loss).

## Structure
PDK4 (pyruvate dehydrogenase kinase 4) is a member of the GHKL ATPase/kinase superfamily, characterized by a conserved ATP-binding fold. The primary structure of PDK4 consists of a sequence of amino acids that form the protein, which is involved in the regulation of the pyruvate dehydrogenase complex (PDC) by phosphorylating its E1 component, thus inhibiting its activity (Tso2014Structureguided).

The secondary structure of PDK4 includes alpha helices and beta sheets, which contribute to its overall stability and function. The tertiary structure of PDK4 involves the three-dimensional folding of the protein, which includes a kinase domain crucial for its enzymatic activity. This domain is responsible for the transfer of phosphate groups to specific serine residues on the E1 component of PDC (Patel2003The).

PDK4 can form homodimers, representing its quaternary structure. In its dimeric form, PDK4 has a head-to-head orientation with primary interactions occurring between the C-terminal domains of each monomer (Patel2014The). Post-translational modifications, such as phosphorylation, can regulate the activity of PDK4, influencing its role in metabolic processes (KOLOBOVA2001Regulation).

## Function
Pyruvate dehydrogenase kinase 4 (PDK4) is a mitochondrial enzyme that plays a crucial role in regulating the pyruvate dehydrogenase complex (PDC), which is essential for converting pyruvate into acetyl-CoA, a key substrate for the tricarboxylic acid (TCA) cycle. By phosphorylating the E1 component of PDC, PDK4 inhibits its activity, thereby controlling the switch between glucose and fatty acid oxidation in cells (Jeon2020Loss; Jeoung2010Role).

In healthy human cells, PDK4 expression is tightly regulated by nutritional and hormonal signals. During fasting or low insulin conditions, PDK4 is upregulated, promoting fatty acid oxidation over glucose oxidation. This regulation is mediated by transcription factors such as FOXO1 and PPARs, which respond to changes in insulin and glucocorticoid levels (Jeon2020Loss; Connaughton2010Regulation). In the fed state, insulin signaling suppresses PDK4 expression, favoring glucose oxidation (Kim2023The).

PDK4 is particularly active in tissues with high metabolic demands, such as skeletal muscle, liver, and heart, where it helps maintain energy homeostasis by modulating the balance between carbohydrate and lipid metabolism (Jeon2020Loss; Jeoung2010Role). This dynamic regulation is crucial for metabolic flexibility and energy efficiency in response to varying physiological conditions.

## Clinical Significance
Alterations in the expression of the PDK4 gene are implicated in various metabolic and cardiovascular diseases. In Doberman Pinschers, a splice site mutation in PDK4 is associated with dilated cardiomyopathy (DCM), leading to increased pyruvate dehydrogenase (PDH) activity and decreased mitochondrial function, which may serve as an early biomarker for DCM risk (Bolfer2020Functional). In humans, PDK4 overexpression is linked to metabolic diseases such as obesity, diabetes, and cancer cachexia, where it contributes to mitochondrial dysfunction and muscle atrophy (Pin2019PDK4; Jeon2020Loss).

In cancer, PDK4 is involved in tumorigenesis through the activation of the CREB-RHEB-mTORC1 signaling cascade, promoting cell growth and proliferation (Liu2014PDK4). High PDK4 expression is associated with poor prognosis in gastric cancer, as it enhances cell proliferation and metastasis (Liu2021Increased). Conversely, in colorectal liver metastases, high hepatic PDK4 expression is linked to improved survival, particularly in patients undergoing neoadjuvant chemotherapy (Strowitzki2019High).

PDK4 also plays a role in muscle-related conditions, where its increased activity is associated with mitochondrial dysfunction, contributing to muscle pathologies like sarcopenia and insulin resistance (Kim2023The).

## Interactions
PDK4 (pyruvate dehydrogenase kinase 4) is involved in several protein interactions that influence its function and role in cellular processes. PDK4 interacts with the IP3R1-GRP75-VDAC1 complex at the mitochondria-associated membrane (MAM) interface, which is crucial for calcium transfer between the endoplasmic reticulum (ER) and mitochondria. This interaction is significant in skeletal muscle, particularly during obesity, where it enhances MAM formation and affects insulin signaling (Thoudam2018PDK4).

PDK4 also interacts with the inner lipoyl-bearing domain (L2) of the transacetylase component of the pyruvate dehydrogenase complex (PDC), although it shows a weaker affinity compared to other PDK isoenzymes (TUGANOVA2002Interaction). This interaction is important for the regulation of the PDC activity.

In the context of cancer, PDK4 is involved in the activation of the mTORC1 signaling pathway. It interacts with the cAMP-response element-binding protein (CREB), stabilizing it and preventing its degradation. This interaction enhances the transcription of RHEB, a key activator of mTORC1, thereby promoting tumorigenesis (Liu2014PDK4). These interactions highlight PDK4's role in metabolic regulation and disease pathogenesis.


## References


[1. (Patel2003The) Mulchand S. Patel and Lioubov G. Korotchkina. The biochemistry of the pyruvate dehydrogenase complex*. Biochemistry and Molecular Biology Education, 31(1):5–15, January 2003. URL: http://dx.doi.org/10.1002/bmb.2003.494031010156, doi:10.1002/bmb.2003.494031010156. This article has 69 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/bmb.2003.494031010156)

[2. (Patel2014The) Mulchand S. Patel, Natalia S. Nemeria, William Furey, and Frank Jordan. The pyruvate dehydrogenase complexes: structure-based function and regulation. Journal of Biological Chemistry, 289(24):16615–16623, June 2014. URL: http://dx.doi.org/10.1074/jbc.r114.563148, doi:10.1074/jbc.r114.563148. This article has 452 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.r114.563148)

[3. (Kim2023The) Min-Ji Kim, Ibotombi Singh Sinam, Zerwa Siddique, Jae-Han Jeon, and In-Kyu Lee. The link between mitochondrial dysfunction and sarcopenia: an update focusing on the role of pyruvate dehydrogenase kinase 4. Diabetes &amp; Metabolism Journal, 47(2):153–163, March 2023. URL: http://dx.doi.org/10.4093/dmj.2022.0305, doi:10.4093/dmj.2022.0305. This article has 10 citations.](https://doi.org/10.4093/dmj.2022.0305)

[4. (Jeon2020Loss) Jae‐Han Jeon, Themis Thoudam, Eun Jung Choi, Min‐Ji Kim, Robert A Harris, and In‐Kyu Lee. Loss of metabolic flexibility as a result of overexpression of pyruvate dehydrogenase kinases in muscle, liver and the immune system: therapeutic targets in metabolic diseases. Journal of Diabetes Investigation, 12(1):21–31, September 2020. URL: http://dx.doi.org/10.1111/jdi.13345, doi:10.1111/jdi.13345. This article has 33 citations and is from a peer-reviewed journal.](https://doi.org/10.1111/jdi.13345)

[5. (Jeoung2010Role) Nam Ho Jeoung and Robert A. Harris. Role of pyruvate dehydrogenase kinase 4 in regulation of blood glucose levels. Korean Diabetes Journal, 34(5):274, 2010. URL: http://dx.doi.org/10.4093/kdj.2010.34.5.274, doi:10.4093/kdj.2010.34.5.274. This article has 57 citations.](https://doi.org/10.4093/kdj.2010.34.5.274)

[6. (Liu2021Increased) Bin Liu, Yang Zhang, and Jian Suo. Increased expression of pdk4 was displayed in gastric cancer and exhibited an association with glucose metabolism. Frontiers in Genetics, June 2021. URL: http://dx.doi.org/10.3389/fgene.2021.689585, doi:10.3389/fgene.2021.689585. This article has 14 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fgene.2021.689585)

[7. (Liu2014PDK4) Zhibo Liu, Xinxin Chen, Ying Wang, Haiyong Peng, Yanan Wang, Yanling Jing, and Hongbing Zhang. Pdk4 protein promotes tumorigenesis through activation of camp-response element-binding protein (creb)-ras homolog enriched in brain (rheb)-mtorc1 signaling cascade. Journal of Biological Chemistry, 289(43):29739–29749, October 2014. URL: http://dx.doi.org/10.1074/jbc.m114.584821, doi:10.1074/jbc.m114.584821. This article has 69 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m114.584821)

[8. (Connaughton2010Regulation) Sara Connaughton, Farhana Chowdhury, Ramy R. Attia, Shulan Song, Yi Zhang, Marshall B. Elam, George A. Cook, and Edwards A. Park. Regulation of pyruvate dehydrogenase kinase isoform 4 (pdk4) gene expression by glucocorticoids and insulin. Molecular and Cellular Endocrinology, 315(1–2):159–167, February 2010. URL: http://dx.doi.org/10.1016/j.mce.2009.08.011, doi:10.1016/j.mce.2009.08.011. This article has 160 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.mce.2009.08.011)

[9. (Tso2014Structureguided) Shih-Chia Tso, Xiangbing Qi, Wen-Jun Gui, Cheng-Yang Wu, Jacinta L. Chuang, Ingrid Wernstedt-Asterholm, Lorraine K. Morlock, Kyle R. Owens, Philipp E. Scherer, Noelle S. Williams, Uttam K. Tambar, R. Max Wynn, and David T. Chuang. Structure-guided development of specific pyruvate dehydrogenase kinase inhibitors targeting the atp-binding pocket. Journal of Biological Chemistry, 289(7):4432–4443, February 2014. URL: http://dx.doi.org/10.1074/jbc.M113.533885, doi:10.1074/jbc.m113.533885. This article has 102 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.M113.533885)

[10. (Strowitzki2019High) Moritz J. Strowitzki, Praveen Radhakrishnan, Sandra Pavicevic, Jana Scheer, Gwendolyn Kimmer, Alina S. Ritter, Christopher Tuffs, Claudia Volz, Florian Vondran, Jonathan M. Harnoss, Johannes Klose, Thomas Schmidt, and Martin Schneider. High hepatic expression of pdk4 improves survival upon multimodal treatment of colorectal liver metastases. British Journal of Cancer, 120(7):675–688, February 2019. URL: http://dx.doi.org/10.1038/s41416-019-0406-9, doi:10.1038/s41416-019-0406-9. This article has 16 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/s41416-019-0406-9)

[11. (KOLOBOVA2001Regulation) Elena KOLOBOVA, Alina TUGANOVA, Igor BOULATNIKOV, and Kirill M. POPOV. Regulation of pyruvate dehydrogenase activity through phosphorylation at multiple sites. Biochemical Journal, 358(1):69, August 2001. URL: http://dx.doi.org/10.1042/0264-6021:3580069, doi:10.1042/0264-6021:3580069. This article has 39 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1042/0264-6021:3580069)

[12. (Bolfer2020Functional) Luiz Bolfer, Amara H. Estrada, Chelsea Larkin, Thomas J. Conlon, Francisco Lourenco, Kathryn Taggart, Silveli Suzuki-Hatano, and Christina A. Pacak. Functional consequences of pdk4 deficiency in doberman pinscher fibroblasts. Scientific Reports, March 2020. URL: http://dx.doi.org/10.1038/s41598-020-60879-6, doi:10.1038/s41598-020-60879-6. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-020-60879-6)

[13. (Pin2019PDK4) Fabrizio Pin, Leah J. Novinger, Joshua R. Huot, Robert A. Harris, Marion E. Couch, Thomas M. O’Connell, and Andrea Bonetto. Pdk4 drives metabolic alterations and muscle atrophy in cancer cachexia. The FASEB Journal, 33(6):7778–7790, March 2019. URL: http://dx.doi.org/10.1096/fj.201802799r, doi:10.1096/fj.201802799r. This article has 49 citations.](https://doi.org/10.1096/fj.201802799r)

[14. (Thoudam2018PDK4) Themis Thoudam, Chae-Myeong Ha, Jaechan Leem, Dipanjan Chanda, Jong-Seok Park, Hyo-Jeong Kim, Jae-Han Jeon, Yeon-Kyung Choi, Suthat Liangpunsakul, Yang Hoon Huh, Tae-Hwan Kwon, Keun-Gyu Park, Robert A. Harris, Kyu-Sang Park, Hyun-Woo Rhee, and In-Kyu Lee. Pdk4 augments er–mitochondria contact to dampen skeletal muscle insulin signaling during obesity. Diabetes, 68(3):571–586, December 2018. URL: http://dx.doi.org/10.2337/db18-0363, doi:10.2337/db18-0363. This article has 133 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.2337/db18-0363)

[15. (TUGANOVA2002Interaction) Alina TUGANOVA, Igor BOULATNIKOV, and Kirill M. POPOV. Interaction between the individual isoenzymes of pyruvate dehydrogenase kinase and the inner lipoyl-bearing domain of transacetylase component of pyruvate dehydrogenase complex. Biochemical Journal, 366(1):129–136, August 2002. URL: http://dx.doi.org/10.1042/bj20020301, doi:10.1042/bj20020301. This article has 42 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1042/bj20020301)